within Pharmacolibrary.Drugs.ATC.B;

model B01AD01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 1.0,
    adminDuration  = 600,
    adminMass      = 1500.0,
    adminCount     = 1,
    Vd             = 0.00011999999999999999,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Streptokinase is a thrombolytic agent that acts by activating plasminogen to form plasmin, leading to the dissolution of blood clots. It is indicated for the treatment of acute myocardial infarction, pulmonary embolism, and deep vein thrombosis. While previously widely used, it has largely been replaced by newer agents in many countries due to potential allergic reactions and the availability of recombinant alternatives.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic data reported in adult patients with acute myocardial infarction receiving intravenous infusion.</p><h4>References</h4><ol><li><p>Grierson, DS, &amp; Bjornsson, TD (1987). Pharmacokinetics of streptokinase in patients based on amidolytic activator complex activity. <i>Clinical pharmacology and therapeutics</i> 41(3) 304–313. DOI:<a href=&quot;https://doi.org/10.1038/clpt.1987.32&quot;>10.1038/clpt.1987.32</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3816018/&quot;>https://pubmed.ncbi.nlm.nih.gov/3816018</a></p></li><li><p>Jin, SE, et al., &amp; Kim, CK (2015). Comparative effects of PEG-containing liposomal formulations on in vivo pharmacokinetics of streptokinase. <i>Archives of pharmacal research</i> 38(10) 1822–1829. DOI:<a href=&quot;https://doi.org/10.1007/s12272-015-0594-7&quot;>10.1007/s12272-015-0594-7</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25851624/&quot;>https://pubmed.ncbi.nlm.nih.gov/25851624</a></p></li><li><p>Battershill, PE, et al., &amp; Goa, KL (1994). Streptokinase. A review of its pharmacology and therapeutic efficacy in acute myocardial infarction in older patients. <i>Drugs &amp; aging</i> 4(1) 63–86. DOI:<a href=&quot;https://doi.org/10.2165/00002512-199404010-00007&quot;>10.2165/00002512-199404010-00007</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8130384/&quot;>https://pubmed.ncbi.nlm.nih.gov/8130384</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end B01AD01;
